Osborne Clarke has advised Breath Therapeutics in the EUR 43.5 million Series A financing round co-led by Gimv and Sofinnova Partners and joined by Gilde Healthcare.

Breath Therapeutics, a spin-off of PARI Pharma, develops advanced drug-aerosol therapeutics in pulmonary orphan indications. The funding will enable the company to conduct Phase III trials in Europe and the US, submit for marketing approval and prepare for commercialization.

The Osborne Clarke Netherlands team was led by Partner Herke van Hulst, who was assisted by Senior Associate Geoffrey Beurskens and Associate Niels Dolk.